Lyrica

Total: $228.9 million
Fibromyalgia: $123.1 million
Diabetic neuropathy: $105.7 million

In 2014, Pfizer ($PFE), which spends more than a billion dollars on DTC spending, put its biggest ad spending bet on its blockbuster drug Lyrica. Paid media was split almost evenly between the drug's two approved indications, fibromyalgia and diabetic nerve pain. Advertising for the former indication generally focused on fibromyalgia sufferers becoming more active, while ads for the latter featured individual older adults telling their personal stories of diabetic pain management.

Pfizer's top seller continued to bring home significant sales last year, with $5.2 billion in sales--an increase of more than 12%. It accounts for more than 10% of Pfizer's total revenue.

Pfizer recently caused a stir in the U.K. when it went after doctors for prescribing biosimilar generics for pain; Lyrica is off patent for epilepsy and general anxiety in England, but Pfizer still holds a patent for Lyrica for treating pain. Lyrica recently got court backing to keep patent exclusivity in the U.S. through 2018.

For more:
Pfizer's Lyrica team matches the spokesman to the message
Pfizer's Lyrica patent fight in England puts NHS docs, pharmacists on defensive
Don't use generic Lyrica for pain, Pfizer warns U.K. providers--or else
Lyrica matches UCB drug in Pfizer's latest epilepsy trial
Pfizer whiffs in PhIII study with controlled-release Lyrica

Lyrica
Read more on

Suggested Articles

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.

Without any new data, Sarepta appealed an FDA rejection and got a surprising nod for Vyondys 53—its second med approved on a surrogate marker.

Roche’s Tecentriq and Cotellic pairing went 0 for 1 in phase 3 melanoma trials—but Friday, they reversed that trend in a Zelboraf combo test.